ClinicalTrials.gg
CompletedNCT01477411Updated Jan 18, 2012

A Drug-Drug Interaction Study of Digoxin and PA21

A Phase 1 interventional study of PA21 and Digoxin in Drug Interaction Potentiation, sponsored by Vifor Pharma. Completed at 1 site in United States. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-01-18.

Sponsored by Vifor Pharma (part of CSL Limited) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to determine if Digoxin is affected by PA21.

02

Conditions studied

  • Drug Interaction Potentiation

Keywords

  • Drug-drug interaction
  • Pharmacokinetics
  • PA21
03

In context

Lead sponsor

Vifor Pharma is the lead sponsor of 22 studies on the registry; none are open to participants now.

First submitted before Vifor Pharma became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers
  • Written

Exclusion criteria

Exclusion Criteria:

  • No significant medical conditions
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    PA21 and Digoxin with food

    The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Digoxin will be 0.5 mg/day

    Drug: PA21 · Drug: Digoxin

  • Experimental
    No PA21; Digoxin with food

    The maximum dosage of Digoxin will be 0.5 mg/day

    Drug: Digoxin

  • Experimental
    PA21 with food and Digoxin 2hrs later

    The maximum dose of PA21 will be 15 g/day. The maximum dose of Digoxin will be 0.5 mg/day

    Drug: PA21 · Drug: Digoxin

Interventions

  • DrugPA21

    The maximum dose of PA21 will be 15.0 g/day.

  • The maximum dosage of Digoxin will be 0.5 mg/day

06

What researchers measure

Primary outcomes

  1. Area Under the Curve from time zero to 24 hours (AUC0-24)

    Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours

    Time frame: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post digoxin dose on Days 0, 11, 22

  2. Area Under the Curve from time zero to infinite (AUC0-infinity)

    Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time

    Time frame: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post Digoxin dose on Days 0, 11, 22

  3. Maximum observed plasma concentration (Cmax)

    Time frame: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post Digoxin dose on days 0, 11, 22

07

Study locations

1 site
  • ACRI - Phase 1
    Anaheim, California 92801, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2011
First posted
Nov 22, 2011
Start
Nov 2011
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Last update
Jan 18, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01477411
Lead sponsor
Vifor Pharma
Responsible party
Sponsor
First posted
Nov 22, 2011
Start date
Nov 2011
Primary completion
Jan 2012
Completion
Jan 2012
Last update
Jan 18, 2012

Study contacts

Peter Winkle, MD
principal investigator · ACRI - Phase 1 (Advanced Clinical Research Institute)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PA21 · Digoxin

Start the discussion